Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study).

Tsai JN, Uihlein AV, Burnett-Bowie SM, Neer RM, Derrico NP, Lee H, Bouxsein ML, Leder BZ

The Journal of clinical endocrinology and metabolism10 Mar 2016Cited by 84 (Europe PMC)

PMID26964731PMCIDPMC4870854DOI10.1210/jc.2016-1160PepBankPUB-26964731

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, adding teriparatide to denosumab increased radius total vBMD more than denosumab alone.
In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased radius total bone density more than denosumab alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius total vBMD: addition to denosumab
Study
n: not reported in source
Comparator
denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 2 yearsAs given in this study (human).
Source sentences
Summary
Total volumetric bone mineral density (vBMD) at the radius and tibia, trabecular vBMD at the radius, and cortical vBMD at the tibia all increased more in the combination group than both monotherapy groups (P < .002 for all comparisons with combination).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
Report a problemFND-2696473101
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, adding teriparatide to denosumab increased tibia total vBMD more than denosumab alone.
In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased tibia total bone density more than denosumab alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia total vBMD: addition to denosumab
Study
n: not reported in source
Comparator
denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 2 yearsAs given in this study (human).
Source sentences
Summary
Total volumetric bone mineral density (vBMD) at the radius and tibia, trabecular vBMD at the radius, and cortical vBMD at the tibia all increased more in the combination group than both monotherapy groups (P < .002 for all comparisons with combination).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
Report a problemFND-2696473103
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, adding teriparatide to denosumab increased radius trabecular vBMD more than denosumab alone.
In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased radius trabecular bone density more than denosumab alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius trabecular vBMD: addition to denosumab
Study
n: not reported in source
Comparator
denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 2 yearsAs given in this study (human).
Source sentences
Summary
Total volumetric bone mineral density (vBMD) at the radius and tibia, trabecular vBMD at the radius, and cortical vBMD at the tibia all increased more in the combination group than both monotherapy groups (P < .002 for all comparisons with combination).
3 context sentences(design, population, supporting numbers)
Summary · context
Trabecular vBMD at the tibia increased similarly in all groups, whereas radius trabecular vBMD increased more in the combination group than the other groups (P < .01 for both comparisons).
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
Report a problemFND-2696473105
04HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, adding teriparatide to denosumab increased tibia cortical vBMD more than denosumab alone.
In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased tibia cortical bone density more than denosumab alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia cortical vBMD: addition to denosumab
Study
n: not reported in source
Comparator
denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 2 yearsAs given in this study (human).
Source sentences
Summary
Total volumetric bone mineral density (vBMD) at the radius and tibia, trabecular vBMD at the radius, and cortical vBMD at the tibia all increased more in the combination group than both monotherapy groups (P < .002 for all comparisons with combination).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
Report a problemFND-2696473107
05HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, adding teriparatide to denosumab increased tibia cortical thickness more than denosumab alone.
In plain wordsIn women with osteoporosis, adding teriparatide to denosumab increased tibia cortical thickness more than denosumab alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia cortical thickness: addition to denosumab
Study
n: not reported in source
Comparator
denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 2 yearsAs given in this study (human).
Measurements
Tibia cortical thickness change
8.1%
teriparatide plus denosumab group, reported with ± 4.3%
Source sentences
Summary
Cortical thickness at the tibia also increased more in the combination group (8.1% ± 4.3%) than both other groups (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
Report a problemFND-2696473109
06HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, radius cortical porosity increased with teriparatide but remained stable with denosumab.
In plain wordsIn women with osteoporosis, radius cortical porosity increased with teriparatide but stayed stable with denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius cortical porosity versus denosumab
Study
n: not reported in source
Comparator
denosumab
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 2 yearsAs given in this study (human).
Source sentences
Summary
Cortical porosity at both the radius and tibia increased progressively over the 24-month treatment period in the teriparatide group but was stable in both other groups (P < .001 teriparatide vs both other groups).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
Report a problemFND-2696473111
07HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, tibia cortical porosity increased with teriparatide but remained stable with denosumab.
In plain wordsIn women with osteoporosis, tibia cortical porosity increased with teriparatide but stayed stable with denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia cortical porosity versus denosumab
Study
n: not reported in source
Comparator
denosumab
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 2 yearsAs given in this study (human).
Source sentences
Summary
Cortical porosity at both the radius and tibia increased progressively over the 24-month treatment period in the teriparatide group but was stable in both other groups (P < .001 teriparatide vs both other groups).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
Report a problemFND-2696473113

Studies that did not test the peptide alone9

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, tibia trabecular vBMD increased similarly in all groups, including teriparatide.
In plain wordsIn women with osteoporosis, tibia trabecular bone density increased similarly with teriparatide, denosumab, and their combination.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTibia trabecular vBMD across all groups
Study
n = 94
Comparator
all treatment groups
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Trabecular vBMD at the tibia increased similarly in all groups, whereas radius trabecular vBMD increased more in the combination group than the other groups (P < .01 for both comparisons).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2696473115
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, finite element estimated strength at the radius and tibia improved or was maintained with all treatments, including teriparatide.
In plain wordsIn women with osteoporosis, estimated bone strength improved or stayed stable with every treatment, including teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedEstimated bone strength at radius and tibia across all groups
Study
n = 94
Comparator
all treatment groups
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Finite element analysis-estimated strength improved or was maintained by all treatments at both the radius and tibia.
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2696473116
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined denosumab and teriparatide increased radius total vBMD more than teriparatide alone.
In plain wordsIn women with osteoporosis, combination therapy increased radius total bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius total vBMD: combination versus teriparatide
Study
n: not reported in source
Comparator
teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Total volumetric bone mineral density (vBMD) at the radius and tibia, trabecular vBMD at the radius, and cortical vBMD at the tibia all increased more in the combination group than both monotherapy groups (P < .002 for all comparisons with combination).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2696473102
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined denosumab and teriparatide increased tibia total vBMD more than teriparatide alone.
In plain wordsIn women with osteoporosis, combination therapy increased tibia total bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia total vBMD: combination versus teriparatide
Study
n: not reported in source
Comparator
teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Total volumetric bone mineral density (vBMD) at the radius and tibia, trabecular vBMD at the radius, and cortical vBMD at the tibia all increased more in the combination group than both monotherapy groups (P < .002 for all comparisons with combination).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2696473104
12HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined denosumab and teriparatide increased radius trabecular vBMD more than teriparatide alone.
In plain wordsIn women with osteoporosis, combination therapy increased radius trabecular bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius trabecular vBMD: combination versus teriparatide
Study
n: not reported in source
Comparator
teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Total volumetric bone mineral density (vBMD) at the radius and tibia, trabecular vBMD at the radius, and cortical vBMD at the tibia all increased more in the combination group than both monotherapy groups (P < .002 for all comparisons with combination).
3 context sentences(design, population, supporting numbers)
Summary · context
Trabecular vBMD at the tibia increased similarly in all groups, whereas radius trabecular vBMD increased more in the combination group than the other groups (P < .01 for both comparisons).
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2696473106
13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined denosumab and teriparatide increased tibia cortical vBMD more than teriparatide alone.
In plain wordsIn women with osteoporosis, combination therapy increased tibia cortical bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia cortical vBMD: combination versus teriparatide
Study
n: not reported in source
Comparator
teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Total volumetric bone mineral density (vBMD) at the radius and tibia, trabecular vBMD at the radius, and cortical vBMD at the tibia all increased more in the combination group than both monotherapy groups (P < .002 for all comparisons with combination).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2696473108
14HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined denosumab and teriparatide increased tibia cortical thickness more than teriparatide alone.
In plain wordsIn women with osteoporosis, combination therapy increased tibia cortical thickness more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTibia cortical thickness: combination versus teriparatide
Study
n: not reported in source
Comparator
teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Measurements
Tibia cortical thickness change
8.1%
teriparatide plus denosumab group, reported with ± 4.3%
Source sentences
Summary
Cortical thickness at the tibia also increased more in the combination group (8.1% ± 4.3%) than both other groups (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2696473110
15HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, radius cortical porosity increased with teriparatide alone but remained stable with combined denosumab and teriparatide.
In plain wordsIn women with osteoporosis, radius cortical porosity rose with teriparatide alone but stayed stable with denosumab plus teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadius cortical porosity: combination versus teriparatide
Study
n: not reported in source
Comparator
teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Cortical porosity at both the radius and tibia increased progressively over the 24-month treatment period in the teriparatide group but was stable in both other groups (P < .001 teriparatide vs both other groups).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2696473112
16HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, tibia cortical porosity increased with teriparatide alone but remained stable with combined denosumab and teriparatide.
In plain wordsIn women with osteoporosis, tibia cortical porosity rose with teriparatide alone but stayed stable with denosumab plus teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTibia cortical porosity: combination versus teriparatide
Study
n: not reported in source
Comparator
teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Cortical porosity at both the radius and tibia increased progressively over the 24-month treatment period in the teriparatide group but was stable in both other groups (P < .001 teriparatide vs both other groups).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an open-label, randomized controlled trial.
Summary · context
We performed high-resolution peripheral quantitative computed tomography at the distal tibia and radius in 94 postmenopausal osteoporotic women randomized to 2 years of teriparatide 20 μg sc daily, denosumab 60 mg sc every 6 months, or both.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2696473114

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00926380

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

Massachusetts General Hospitaln = 94Jun 2009 to Dec 2016

Osteoporosis

Trial page ClinicalTrials.govUpdated 29 Jun 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.